Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Glaxosmithkline Plc's ViiV Healthcare Ltd Announces Positive CHMP Opinion on Tivicay for Treatment of HIV


Friday, 22 Nov 2013 08:43am EST 

Glaxosmithkline Plc announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing authorisation for ViiV Healthcare's Tivicay (dolutegravir) for use in combination with other antiretroviral medicinal products for the treatment of HIV-infected adults and adolescents above 12 years of age. A CHMP positive opinion is one of the final steps in the regulatory process leading to the marketing authorisation decision of the European Commission, which is expected early in 2014. ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline. 

Company Quote

17.838
0.578 +3.35%
10:03am EDT